# US 2019/0315828 A1 · Insulin-fc fusions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315828 A1
- Document ID: US20190315828A1
- Status: Published application
- Kind: A1
- Application number: 16/438,681
- Filed: 2019-06-12
- Published: 2019-10-17
- Earliest claimed: 2016-12-09
- Assignees: Akston Biosciences Corporation
- Applicants: Akston Biosciences Corporation
- Inventors: Thomas M. Lancaster; Todd C. Zion; Thillainayagam Sathiyaseelan; Sylaja Murikipudi
- Web page: https://patentgrep.com/patent/US20190315828A1

## CPC

- C07K 14/62: Insulins
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.

## Claims

### Claim 1

An insulin-Fc fusion protein comprising an insulin polypeptide fused to a Fc domain, wherein the insulin polypeptide comprises a B-chain peptide, a C-chain peptide, and an A-chain peptide, wherein the amino acid sequence of the C-chain peptide is AAK (SEQ ID NO: 16), and optionally wherein the insulin-Fc fusion protein binds human insulin receptor at an IC50>5,000 nM in a competitive binding assay.

### Claim 2 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the insulin-Fc fusion protein inhibits in vitro binding of insulin+ B cell receptors to insulin at an IC50≥100 nM.

### Claim 3 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the insulin-Fc fusion protein activates T-cells to secrete IL-2 levels that are reduced compared to that observed in T-cells activated by recombinant human insulin.

### Claim 4 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the amino acid sequence of the A-chain peptide comprises SEQ ID NO: 19.

### Claim 5 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the Fc domain comprises a wild-type Fc fragment of human IgG1, and wherein the amino acid sequence of the Fc domain comprises SEQ ID NO: 22.

### Claim 6 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the B-chain peptide comprises the amino acid sequence FVNQHLCGSHLVX1ALX2LVCGEX3GFFYTPK (SEQ ID NO: 28), wherein X1 is E or Q, X2 is Y or A, and X3 is R or E.

### Claim 7 (depends on 1)

The insulin-Fc fusion protein of claim 1, wherein the insulin polypeptide is fused to the Fc fragment via a peptide linker, and wherein the amino acid sequence of the peptide linker is selected from the group consisting of SEQ ID NO: 20 and SEQ ID NO: 21.

### Claim 8

An insulin-Fc fusion protein comprising an insulin polypeptide fused to a Fc domain, wherein the insulin polypeptide comprises a B-chain peptide, a C-chain peptide, and an A-chain peptide,
wherein the B-chain peptide comprises the amino acid sequence FVNQHLCGSHLVX1ALX2LVCGEX3GFFYTPK (SEQ ID NO: 28), wherein X1 is E or Q, X2 is Y or A, and X3 is R or E; and
wherein the amino acid sequence of the C-chain peptide is AAK (SEQ ID NO: 16).

### Claim 9 (depends on 8)

The insulin-Fc fusion protein of claim 8, wherein X2 is A.

### Claim 10 (depends on 8)

The insulin-Fc fusion protein of claim 8, wherein the amino acid sequence of the A-chain peptide comprises SEQ ID NO: 19.

### Claim 11 (depends on 8)

The insulin-Fc fusion protein of claim 8, wherein the Fc domain comprises a wild-type Fc fragment of human IgG1, and wherein the amino acid sequence of the Fc domain comprises SEQ ID NO: 22.

### Claim 12 (depends on 8)

The insulin-Fc fusion protein of claim 8, wherein the insulin polypeptide is fused to the Fc fragment via a peptide linker, and wherein the amino acid sequence of the peptide linker is selected from the group consisting of SEQ ID NO: 20 and SEQ ID NO: 21.

### Claim 13 (depends on 8)

The insulin-Fc fusion protein of claim 8, wherein the amino acid sequence of the insulin-Fc fusion protein is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

### Claim 14

A recombinant nucleic acid sequence encoding an insulin-Fc fusion protein selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 15 (depends on 14)

A vector comprising the recombinant nucleic acid sequence of claim 14, wherein the recombinant nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36.

### Claim 16 (depends on 15)

An engineered eukaryotic cell comprising the vector of claim 15.

### Claim 17 (depends on 1)

A method for treating or preventing autoimmune diabetes in a subject in need thereof comprising administering to the subject an effective amount of the insulin-Fc fusion protein of claim 1, wherein autoimmune diabetes is selected from the group consisting of Type 1 diabetes, juvenile diabetes, insulin-dependent diabetes, and latent autoimmune diabetes;
wherein the subject has been diagnosed with or is at risk for autoimmune diabetes; and
wherein the subject is not hyperglycemic.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject has detectable levels of at least one autoimmune antibody selected from the group consisting of an insulin autoantibody (IAA), an anti-glutamic acid decarboxylase (GAD) antibody, and an anti-islet antigen-2 (IA-2) antibody, and wherein the subject has detectable levels of an insulin-specific B cell population.

### Claim 19 (depends on 17)

The method of claim 17, wherein the subject harbors one or more human leukocyte antigen (HLA) haplotypes selected from the group consisting of: (a) DRB1*0301-DQA1*0501-DQB1*0201; (b) DRB1*0405-DQA1*0301-DQB1*0302; (c) DRB1*0401-DQA1*0301-DQB*0302; (d) DRB1*0402-DQA1*0301-DQB1*0302; (e) DRB1*0404-DQA1*0301-DQB1*0302; and (f) DRB1*0801-DQB1*0401-DQB1*0402.

### Claim 20 (depends on 17)

The method of claim 17, wherein the subject displays a reduction in the number of anti-insulin B cells after at least one administration of the insulin-Fc fusion protein compared to that observed in the subject prior to the at least one administration, wherein the subject displays decreased levels of insulin autoantibody after the at least one administration of the insulin-Fc fusion protein compared to that observed in the subject prior to the at least one administration; and
wherein blood glucose levels of the subject after at least one administration of the insulin-Fc fusion protein are comparable to that observed in the subject prior to the at least one administration.
